As shown in Figures 3A and 3B, the C1 signature very effectively stratified the patients based on clinical outcome, indicating that FOXM1 regulatory sites and associated target genes may play a pivotal role in tumor progression and TAM resistance. This evidence concerns the gene FOXM1 and neoplasm.